NCT07567508Not yet recruiting
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators. Participants are randomized 1:1 into either an early screening or usual care group. * Early screening group : AI- ECG and/or CT-ECV analysis + AF treatment * Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 28 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Samsung Medical Center
- Diseases
- Amyloidosis, Atrial fibrillation
- NCT number
- NCT07567508
What you commit to
- Study type: Interventional
- Planned participants: 500
- From 1 May 2026 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).
Other illness
- Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.
Other
- Patients deemed inappropriate for participation by the investigator.
Who the study is looking for
- Adults aged 19 or older who have provided voluntary written informed consent.
- Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms/signs.
- Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.